| First Author | Strobl K | Year | 2024 |
| Journal | EMBO Mol Med | Volume | 16 |
| Issue | 12 | Pages | 3142-3168 |
| PubMed ID | 39521937 | Mgi Jnum | J:359563 |
| Mgi Id | MGI:7787421 | Doi | 10.1038/s44321-024-00166-3 |
| Citation | Strobl K, et al. (2024) JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia. EMBO Mol Med 16(12):3142-3168 |
| abstractText | The hair follicle stem cell niche is an immune-privileged microenvironment, characterized by reduced antigen presentation, thus shielding against permanent immune-mediated tissue damage. In this study, we demonstrated the protective role of hair follicle-specific epidermal growth factor receptor (EGFR) against scarring hair follicle destruction. Mechanistically, disruption of EGFR signaling generated a cell-intrinsic hypersensitivity within the JAK-STAT1 pathway, which, synergistically with interferon gamma expressing CD8 T-cell and NK-cell-mediated inflammation, compromised the stem cell niche. Hair follicle-specific genetic depletion of either JAK1/2 or STAT1 or therapeutic inhibition of JAK1/2 ameliorated the inflammation, restored skin barrier function and activated the residual stem cells to resume hair growth in mouse models of epidermal and hair follicle-specific EGFR deletion. Skin biopsies from EGFR inhibitor-treated and cicatricial alopecia patients revealed an active JAK-STAT1 signaling signature along with upregulation of antigen presentation and downregulation of key components of the EGFR pathway. Our findings offer molecular insights and highlight a mechanism-based therapeutic strategy for addressing chronic folliculitis associated with EGFR-inhibitor anti-cancer therapy and cicatricial alopecia. |
